The company said a “new analysis of a larger dataset” showed that the drug, aducanumab, reduced clinical decline in patients with early Alzheimer’s disease on multiple measures of the drug’s effectiveness. That directly contradicts a decision in March to halt studies of the therapy based on the recommendations of an independent monitoring board that was charged with protecting patients in the study.
https://www.statnews.com/2019/10/22/biogen-to-submit-aducanumab/
https://www.statnews.com/2019/10/22/biogen-to-submit-aducanumab/